FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2118214176> ?p ?o ?g. }

• W2118214176 abstract "Olodaterol is a novel, inhaled long-acting β2-agonist (LABA) with >24-hour duration of action investigated in asthma and chronic obstructive pulmonary disease.Two multicentre studies examined the efficacy and safety of 4 weeks' once-daily (QD) olodaterol (2, 5, 10 and 20 μg, with background inhaled corticosteroids) in patients with asthma. One randomised, double-blind, parallel-group study (1222.6; 296 patients) administered treatment in the morning. Pulmonary function tests (PFTs) were performed pre-dose (trough) and ≤3 hours post-dose (weeks 1 and 2), and ≤6 hours post-dose after 4 weeks; primary end point was trough forced expiratory volume in 1 second (FEV1) response (change from baseline mean FEV1) after 4 weeks. A second randomised, double-blind, placebo- and active-controlled (formoterol 12 μg twice-daily) incomplete-block crossover study (1222.27; 198 patients) administered QD treatments in the evening. PFTs were performed over a 24-hour dosing interval after 4 weeks; primary end point was FEV1 area under the curve from 0-24 hours (AUC0-24) response (change from study baseline [mean FEV1] after 4 weeks).Study 1222.6 showed a statistically significant increase in trough FEV1 response with olodaterol 20 μg (0.147 L; 95 % confidence interval [CI]: 0.059, 0.234; p = 0.001) versus placebo, with more limited efficacy and no evidence of dose response compared to placebo across the other olodaterol doses (2, 5 and 10 μg). Study 1222.27 demonstrated increases in FEV1 AUC0-24 responses at 4 weeks with all active treatments (p < 0.0001); adjusted mean (95 % CI) differences from placebo were 0.140 (0.097, 0.182), 0.182 (0.140, 0.224), 0.205 (0.163, 0.248) and 0.229 (0.186, 0.272) L for olodaterol 2, 5, 10 and 20 μg, respectively, and 0.169 (0.126, 0.211) for formoterol, providing evidence of increased efficacy with higher olodaterol dose. Olodaterol was generally well tolerated, with a few events associated with known sympathomimetic effects, mainly with 20 μg.The LABA olodaterol has >24-hour duration of action. In patients with asthma, evidence of bronchodilator efficacy was demonstrated with statistically and clinically significant improvements in the primary end point of trough FEV1 response measured in clinics over placebo for the highest administered dose of 20 μg in Study 1222.6, and statistically and clinically significant improvements versus placebo in FEV1 AUC0-24 responses at 4 weeks for all doses tested in Study 1222.27, which also exhibited a dose response. Bronchodilator efficacy was seen over placebo for all olodaterol doses for morning and evening peak expiratory flow in both studies. All doses were well tolerated.NCT00467740 (1222.6) and NCT01013753 (1222.27)." @default.
• W2118214176 created "2016-06-24" @default.
• W2118214176 creator A5001539303 @default.
• W2118214176 creator A5011708772 @default.
• W2118214176 creator A5022294132 @default.
• W2118214176 creator A5026242254 @default.
• W2118214176 creator A5040644897 @default.
• W2118214176 creator A5045367608 @default.
• W2118214176 creator A5068068331 @default.
• W2118214176 creator A5068655233 @default.
• W2118214176 creator A5071411347 @default.
• W2118214176 date "2015-08-18" @default.
• W2118214176 modified "2023-10-18" @default.
• W2118214176 title "Dose-finding evaluation of once-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with asthma: results of a parallel-group study and a crossover study" @default.
• W2118214176 cites W1862886500 @default.
• W2118214176 cites W1957150943 @default.
• W2118214176 cites W1986963293 @default.
• W2118214176 cites W1997210895 @default.
• W2118214176 cites W2019445754 @default.
• W2118214176 cites W2038697731 @default.
• W2118214176 cites W2060873423 @default.
• W2118214176 cites W2106512669 @default.
• W2118214176 cites W2109391068 @default.
• W2118214176 cites W2112899768 @default.
• W2118214176 cites W2118132357 @default.
• W2118214176 cites W2121174591 @default.
• W2118214176 cites W2147703657 @default.
• W2118214176 cites W2157442488 @default.
• W2118214176 cites W2171500615 @default.
• W2118214176 cites W2325918405 @default.
• W2118214176 cites W2331824944 @default.
• W2118214176 cites W2335544335 @default.
• W2118214176 cites W4247764358 @default.
• W2118214176 doi "https://doi.org/10.1186/s12931-015-0249-8" @default.
• W2118214176 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4539885" @default.
• W2118214176 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26283085" @default.
• W2118214176 hasPublicationYear "2015" @default.
• W2118214176 type Work @default.
• W2118214176 sameAs 2118214176 @default.
• W2118214176 citedByCount "6" @default.
• W2118214176 countsByYear W21182141762016 @default.
• W2118214176 countsByYear W21182141762017 @default.
• W2118214176 countsByYear W21182141762018 @default.
• W2118214176 countsByYear W21182141762019 @default.
• W2118214176 countsByYear W21182141762021 @default.
• W2118214176 crossrefType "journal-article" @default.
• W2118214176 hasAuthorship W2118214176A5001539303 @default.
• W2118214176 hasAuthorship W2118214176A5011708772 @default.
• W2118214176 hasAuthorship W2118214176A5022294132 @default.
• W2118214176 hasAuthorship W2118214176A5026242254 @default.
• W2118214176 hasAuthorship W2118214176A5040644897 @default.
• W2118214176 hasAuthorship W2118214176A5045367608 @default.
• W2118214176 hasAuthorship W2118214176A5068068331 @default.
• W2118214176 hasAuthorship W2118214176A5068655233 @default.
• W2118214176 hasAuthorship W2118214176A5071411347 @default.
• W2118214176 hasBestOaLocation W21182141761 @default.
• W2118214176 hasConcept C126322002 @default.
• W2118214176 hasConcept C142724271 @default.
• W2118214176 hasConcept C19720800 @default.
• W2118214176 hasConcept C204787440 @default.
• W2118214176 hasConcept C27081682 @default.
• W2118214176 hasConcept C2776042228 @default.
• W2118214176 hasConcept C2776136866 @default.
• W2118214176 hasConcept C2779871671 @default.
• W2118214176 hasConcept C2781018748 @default.
• W2118214176 hasConcept C42219234 @default.
• W2118214176 hasConcept C44249647 @default.
• W2118214176 hasConcept C71924100 @default.
• W2118214176 hasConcept C75603125 @default.
• W2118214176 hasConcept C87813604 @default.
• W2118214176 hasConceptScore W2118214176C126322002 @default.
• W2118214176 hasConceptScore W2118214176C142724271 @default.
• W2118214176 hasConceptScore W2118214176C19720800 @default.
• W2118214176 hasConceptScore W2118214176C204787440 @default.
• W2118214176 hasConceptScore W2118214176C27081682 @default.
• W2118214176 hasConceptScore W2118214176C2776042228 @default.
• W2118214176 hasConceptScore W2118214176C2776136866 @default.
• W2118214176 hasConceptScore W2118214176C2779871671 @default.
• W2118214176 hasConceptScore W2118214176C2781018748 @default.
• W2118214176 hasConceptScore W2118214176C42219234 @default.
• W2118214176 hasConceptScore W2118214176C44249647 @default.
• W2118214176 hasConceptScore W2118214176C71924100 @default.
• W2118214176 hasConceptScore W2118214176C75603125 @default.
• W2118214176 hasConceptScore W2118214176C87813604 @default.
• W2118214176 hasIssue "1" @default.
• W2118214176 hasLocation W21182141761 @default.
• W2118214176 hasLocation W21182141762 @default.
• W2118214176 hasLocation W21182141763 @default.
• W2118214176 hasLocation W21182141764 @default.
• W2118214176 hasLocation W21182141765 @default.
• W2118214176 hasOpenAccess W2118214176 @default.
• W2118214176 hasPrimaryLocation W21182141761 @default.
• W2118214176 hasRelatedWork W1745336096 @default.
• W2118214176 hasRelatedWork W1998365118 @default.
• W2118214176 hasRelatedWork W2020192336 @default.
• W2118214176 hasRelatedWork W2020365157 @default.
• W2118214176 hasRelatedWork W2043038102 @default.
• W2118214176 hasRelatedWork W2067669835 @default.
• W2118214176 hasRelatedWork W2109586110 @default.
• W2118214176 hasRelatedWork W2110119368 @default.

• next